Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial)

Phase 2

Not yet recruiting

• Conditions: Locally advanced rectal cancer

• Registration Number: 2024-515240-24-00
• Lead Sponsor: Grupo Espanol Multidisciplinar En Cancer Digestivo

Brief Summary

1) Pathological complete response (pCR) rate.

Detailed Description

Not available

Study Timeline

• Study First Posted: 2024-11-15
• Last Update Posted: 2024-11-15

Recruitment & Eligibility

• Status: Authorised, recruitment pending
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

• Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.

• Adequate normal organ and marrow function

• Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients

• Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

• Age ≥ 18 years at time of study entry.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Body weight >30kg.

• Biopsy-proven, newly diagnosed primary rectal adenocarcinoma, with the lowest part of the tumour less than 12 cm from the anal verge using a rigid rectoscope or flexible endoscope.

• MSS (microsatellite stable) rectal cancer assessed by local practice (immunohistochemistry or PCR).

• Mandatory tumour and blood samples for translational research.

• High risk MRI-defined rectal cancer

• No contraindications to chemotherapy and radiotherapy.

Exclusion Criteria

• Participation in another clinical study with an investigational product during the last 6 months.

• Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab.

• Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia’s Correction.

• Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.

• Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria

• Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.

• Previous radiotherapy in the pelvic region (e.g. prostate) or previous rectal surgery (e.g.TEM).

• History of allogenic organ transplantation.

• Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]).

• Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.

• History of another primary malignancy

• Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.

• History of active primary immunodeficiency.

• Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.

• Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.

• Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.

• Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.

• Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab monotherapy.

• Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.

• Prior therapy for rectal cancer.

• Presence of metastatic disease or recurrent rectal tumour. Familial Adenomatosis Polyposis coli (FAP), Hereditary Non-Polyposis Colorectal Cancer (HNPCC), active Crohn’s disease or active ulcerative Colitis.

• MSI (microsatellite inestable) rectal cancers assessed by local practice (immunohistochemistry or PCR).

• Extensive growth into cranial part of the sacrum (above S3) or the lumbosacral nerve roots indicating that surgery will never be possible even if substantial tumour down-sizing is seen.

• Known DPD deficiency

• Persistent peripheral neural toxicity > grade 2.

• Intestinal occlusion. Patients with intestinal occlusion due to the primary rectal tumour, that could participate in the study, may be included after a derivative intestinal surgery.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1) Pathological complete response (pCR) rate.		1) Pathological complete response (pCR) rate.

Secondary Outcome Measures

Name	Time	Method
1) Tumor downstaging.		1) Tumor downstaging.
2) Tumor regression grade (TGR).		2) Tumor regression grade (TGR).
3) R0 resection rate.		3) R0 resection rate.
4) Clear circumferential resection margin (CRM) rate.		4) Clear circumferential resection margin (CRM) rate.
5) 3-year disease-free survival (DFS).		5) 3-year disease-free survival (DFS).
6) Toxicity profile (short and long-term).		6) Toxicity profile (short and long-term).
7) Reduction of surgical complications.		7) Reduction of surgical complications.
8) Calculation of the neoadjuvant rectal (NAR) score		8) Calculation of the neoadjuvant rectal (NAR) score

Trial Locations

Locations (10)

Hospital Universitari Vall D Hebron; 🇪🇸 Barcelona, Spain

Hospital Clinic De Barcelona; 🇪🇸 Barcelona, Spain

Hospital General Universitario De Elche; 🇪🇸 Elche, Spain

Fundacion Instituto Valenciano De Oncologia; 🇪🇸 Valencia, Spain

Consorci Sanitari Integral; 🇪🇸 L'hospitalet De Llobregat, Spain

Complexo Hospitalario Universitario A Coruna; 🇪🇸 A Coruna, Spain

Hospital Universitario Miguel Servet; 🇪🇸 Zaragoza, Spain

Parc Tauli Hospital Universitari; 🇪🇸 Sabadell, Spain

Hospital Universitario De Navarra; 🇪🇸 Pamplona, Spain

Hospital Universitario 12 De Octubre; 🇪🇸 Madrid, Spain

Hospital Universitari Vall D Hebron

🇪🇸Barcelona, Spain

Jaume Capdevila

Site contact

934893450

jcapdevila@vhio.net